<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576897</url>
  </required_header>
  <id_info>
    <org_study_id>LI for Portal Hypertenstion</org_study_id>
    <secondary_id>2009698702</secondary_id>
    <nct_id>NCT04576897</nct_id>
  </id_info>
  <brief_title>Liver Incytes for Portal Hypertension</brief_title>
  <official_title>Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Liver Stiffness Measurement Using Liver Incytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sonic Incytes</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross sectional study that evaluates the relationship between LSM (liver stiffness&#xD;
      measurement) by Liver Incytes in patients with cACLD (compensated advanced chronic liver&#xD;
      disease) and manifestations of portal hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the severity of portal hypertension in people with&#xD;
      compensated advanced chronic liver disease (cACLD) who have not undergone liver transplant by&#xD;
      measuring liver stiffness with the Liver Incytes device and to compare the performance of LSM&#xD;
      (liver stiffness measurement) by Liver Incytes for predicting clinically significant portal&#xD;
      hypertension CSPH, esophageal and gastric varices to that of FibroScan® and other&#xD;
      non-invasive blood markers such as MELD, CPT, platelets count, splenomegaly (enlarged&#xD;
      spleen), APRI and FIB4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will undergo quantitative ultrasound with Liver Incytes by a certified technician</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open label study in that all participants will receive the same study procedures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of Liver Incytes measurements to clinical indicators of compensated advanced chronic liver disease (cACLD)</measure>
    <time_frame>two years</time_frame>
    <description>Comparing the ability of the liver stiffness measurements by Liver Incytes to predict the presence of esophageal or gastric varices and portal hypertensive gastropathy in patients with compensated advanced chronic liver disease (cACLD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of Liver Incytes measurements to FibroScan® measurements for liver stiffness and liver steatosis</measure>
    <time_frame>two years</time_frame>
    <description>Comparing the performance of Liver Incytes to that of FibroScan® in the same patient population to determine if either test is more accurate in correlating with compensated advanced chronic liver disease (cACLD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of Liver Incytes measurements to non-invasive blood markers for predicting advanced fibrosis</measure>
    <time_frame>two years</time_frame>
    <description>Comparing the performance of Liver Incytes to that of non-invasive blood based markers such as APRI, FIB4, and NAFLD fibrosis score in predicting advanced fibrosis in biopsy proven NAFLD.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Portal Hypertension</condition>
  <condition>Chronic Advanced Liver Disease</condition>
  <arm_group>
    <arm_group_label>Liver Incytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with compensated advanced chronic liver disease (cACLD) who have not undergone liver transplantation will be scanned with Liver Incytes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liver Incytes</intervention_name>
    <description>Ultrasound elasticity imaging</description>
    <arm_group_label>Liver Incytes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 21 years or older&#xD;
&#xD;
          2. Ability to provide informed consent&#xD;
&#xD;
          3. Planned standard of care upper endoscopy to screen for varices&#xD;
&#xD;
          4. Planned standard of care transjugular liver biopsy with portal pressure measurement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability or refusal to provide informed consent&#xD;
&#xD;
          2. Fasting for less than three hours prior to the scan&#xD;
&#xD;
          3. Subject is a pregnant or lactating female&#xD;
&#xD;
          4. Subject with current, significant alcohol consumption&#xD;
&#xD;
          5. Patients with a pacemaker or defibrillator&#xD;
&#xD;
          6. Acute hepatitis defined as AST/ALT &gt; 500 U/L&#xD;
&#xD;
          7. Ascites&#xD;
&#xD;
          8. post liver transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samer Gawrieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Regina Weber, BS, RRT</last_name>
    <phone>317-278-3584</phone>
    <email>reginaw@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samer Gawrieh, MD</last_name>
    <phone>317-278-1630</phone>
    <email>sgawrieh@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University Division of Gastroenterolgy and Hepatology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Weber, BS, RRT</last_name>
      <phone>317-278-3584</phone>
      <email>reginaw@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Samer Gawrieh, MD</last_name>
      <phone>317-278-1630</phone>
      <email>sgawrieh@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Samer Gawrieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Samer Gawrieh</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

